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UDP-Glucuronosyltransferases (UGTs) are a family of membrane-bound enzymes that 
catalyze glucuronidation of endogenous and exogenous compounds. There are 19 different 
human UGT isoforms. The expression profiles of UGTs in human tissues at mRNA level had 
been studied. However, information regarding their protein levels was limited because of the 
lack of isoform-specific antibodies. In this thesis, first, peptide-specific monoclonal 
antibodies against human UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B4, and 
UGT2B10 were successfully prepared and were used to investigate the UGTs expression at 
protein levels. It was found the tissue distribution of UGT proteins was largely consistent with 
previous reports of mRNA expression. These antibodies would serve as a useful tool for 
further studies of UGTs to evaluate its physiological and pharmacological roles. Second, the 
underlying mechanism of the tissue-specific expression of UGT1A1 and UGT1A10 was 
investigated. UGT1A1 is predominantly expressed in the liver and intestine, but not in the 
kidney. Meanwhile UGT1A10 is exclusively expressed in the gastrointestinal tract but not in 
liver. It was suggested that DNA hypermethylation along with histone H3 hypoacetylation of 
the promoter of UGT1A1 interfere with the binding of hepatocyte nuclear factor (HNF) 1α, 
resulting in the defective expression of UGT1A1 in the kidney. As for UGT1A10, DNA 
hypermethylation and H3K27 trimethylation would interfere with binding of HNF1α and 
caudal type homeobox 2, resulting in the defective expression of UGT1A10 in the human 
liver. This study could provide valuable information on the tissue distribution, interindividual 




UDP-Glucuronosyltransferases (UGTs) are a family of phase II drug-metabolizing 
enzymes that play key roles in the metabolism of endogenous and exogenous compounds. 
They catalyze the formation of glucuronides by the transfer of glucuronic acid from a cofactor 
uridine 5'-diphosphoglucuronic acid to hydroxyl, carboxyl, or amine groups of endogenous 
and exogenous substrates. Human UGTs are classified into two subfamilies, UGT1 and UGT2, 
based on similarities between their amino acid sequences and gene organization. To date, 19 
human UGT isoforms have been identified. The expression profiles of UGTs in human tissues 
at mRNA level had been studied. However, information regarding their protein levels was 
limited because of the lack of isoform-specific antibodies, since UGTs share a high degree of 
amino acid similarities. In this study, first, peptide-specific monoclonal antibodies against 
3 
human UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B4, and UGT2B10 were prepared 
and were used to investigate the UGTs expression at protein levels. Second, the underlying 
mechanism of the tissue-specific expression of UGT1A1 and UGT1A10 were investigated 
focusing on epigenetic mechanism. 
 
Generation of specific monoclonal antibodies against human UGT1A6, UGT1A8, 
UGT1A9, UGT1A10, UGT2B4, and UGT2B10 and evaluation of their protein levels in 
human tissues 
Determination of the protein levels of the individual UGT isoforms in human tissues is 
required for the successful extrapolation of in vitro metabolic data to in vivo clearance. Most 
previous studies evaluating UGT isoform expression were limited to the mRNA level because 
of the high degree of amino acid sequence homology between UGT isoforms that has 
hampered the availability of isoform-specific antibodies. In this study, peptide-specific 
monoclonal antibodies against human UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B4, 
and UGT2B10 were successfully prepared. Using these antibodies, it was demonstrated that 
UGT1A6 and UGT1A9 proteins were expressed in both the kidney and the liver, but not in 
the small intestine, UGT2B4 and UGT2B10 were expressed only in the liver, UGT1A10 was 
expressed only in the small intestine, that are consistent with previous reports of mRNA 
expression. In a panel of 20 individual human livers, the UGT1A6, UGT1A9, UGT2B4, and 
UGT2B10 protein levels exhibited 10-, 9-, 6-, and 7-fold variability, respectively. 
Interestingly, their relative protein levels were not correlated with the corresponding mRNA 
levels, suggesting the importance of evaluating UGT isoform expression at protein levels. 
Thus, specific monoclonal antibodies against UGT1A6, UGT1A8, UGT1A9, UGT1A10, 
UGT2B4, and UGT2B10 were successfully generated and the distribution and relative 
expression levels of their protein in human tissues were evaluated. These antibodies would 
serve as a useful tool for further studies of UGTs to evaluate its physiological, 
pharmacological, and toxicological roles in human tissues. 
 
Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the 
human kidney 
UGT1A1 catalyzes the metabolism of numerous clinically and pharmacologically 
important compounds such as bilirubin and SN-38. UGT1A1 is predominantly expressed in 
the liver and intestine, but not in the kidney. The purpose of this study was to uncover the 
mechanism of the tissue-specific expression of UGT1A1, focusing on its epigenetic regulation. 
Bisulfite sequence analysis revealed that the CpG-rich region near the UGT1A1 promoter (-85 
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to +40) was hypermethylated (83%) in the kidney, whereas it was hypomethylated (24%) in 
the hepatocytes. A chromatin immunoprecipitation (ChIP) assay demonstrated that histone H3 
near the promoter was hypoacetylated in the kidney but was hyperacetylated in the liver; this 
hyperacetylation was accompanied by the recruitment of hepatocyte nuclear factor (HNF) 1α 
to the promoter. The UGT1A1 promoter in human kidney-derived HK-2 cells not expressing 
UGT1A1 was fully methylated, but was relatively unmethylated in human liver-derived 
HuH-7 cells expressing UGT1A1. Treatment with 5-aza-2’-deoxycytidine (5-Aza-dC), an 
inhibitor of DNA methylation, resulted in an increase of UGT1A1 mRNA expression in both 
cell types, but the increase was much larger in HK-2 cells than in HuH-7 cells. 
Overexpression of HNF1α in HK-2 cells resulted in an increase of UGT1A1 mRNA only in 
the presence of 5-Aza-dC. Thus, it was suggested that DNA hypermethylation along with 
histone hypoacetylation interferes with the binding of HNF1α, resulting in the defective 
expression of UGT1A1 in the human kidney.  
 
Tissue-specific expression of human UGT1A10 by epigenetic regulation 
UGT1A10 is exclusively expressed in the small intestine and colon, where it contributes to 
presystemic first-pass metabolism. Previous studies demonstrated that HNF1α and Sp1 as 
well as intestine-specific transcription factor caudal type homeobox (Cdx) 2 are involved in 
the constitutive expression of UGT1A10. However, HNF1α and Sp1 cannot solely account 
for the intestine-specific expression of UGT1A10, because the expression of these 
transcription factors are not confined to intestines, but rather abundantly expressed in the liver, 
where UGT1A10 is absent. The purpose of this study was to elucidate the underlying 
mechanism of tissue-specific expression of UGT1A10. Bisulfite sequence analysis revealed 
that the CpG-rich region around the UGT1A10 promoter (-264 to +117) was hypermethylated 
(89%) in the epithelium of small intestine, whereas it was hypomethylated (6%) in the 
hepatocytes. Methylation of the UGT1A10 promoter by SssI methylase leads to an almost 
complete loss of transcriptional activity even under the overexpression of Cdx2 and HNF1α. 
The UGT1A10 promoter in human liver-derived HuH-7 cells not expressing UGT1A10 was 
more highly methylated than in human colon-derived LS180 cells expressing UGT1A10. 
Treatment with 5-Aza-dC resulted in a much higher increase of UGT1A10 mRNA expression 
only in HuH-7 cells. Overexpression of HNF1α and Cdx2 resulted in an increase of 
UGT1A10 mRNA only in the presence of 5-Aza-dC in HuH-7 cells. A ChIP assay 
demonstrated that H3K27 around the promoter was trimethylated in the liver but not in the 
small intestine. Thus, DNA hypermethylation and H3K27 trimethylation would interfere with 
binding of HNF1α and Cdx2, resulting in the defective expression of UGT1A10 in the human 
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liver. Epigenetic regulation is a crucial determinant of tissue-specific expression of 
UGT1A10. 
In summary, this study succeeded to prepare peptide-specific monoclonal antibodies 
against human UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B4, and UGT2B10 and 
could provide valuable information on the tissue distribution and interindividual variability of 
UGTs. In addition, it was found that the tissue-specific expression of UGTs is regulated by 
epigenetic mechanism including DNA methylation and histone modifications. Aging, sex, 
disease, and habits are known to affect epigenetic status. It would be of interest to investigate 
whether such factors affect drug response thorough the modulation of epigenetics of UGT.  
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